Dashboard
Manage Tickers

NRBONeuroBo Pharmaceuticals, Inc.

Nasdaq neurobopharma.com


$ 3.81 $ 0.10 (2.73 %)    

Monday, 19-Aug-2024 13:42:04 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.49 $ -1.81 (-0.38 %)
DIA $ 408.64 $ -0.25 (-0.06 %)
SPY $ 558.33 $ -0.83 (-0.15 %)
TLT $ 98.57 $ 0.27 (0.27 %)
GLD $ 232.01 $ -1.71 (-0.73 %)
$ 3.76
$ 3.62 x 400
-- x --
-- - --
$ 2.90 - $ 6.75
14,753
na
20.41M
$ 1.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 04-15-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-20-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-20-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-21-2017 12-31-2016 10-K
32 11-02-2016 09-30-2016 10-Q
33 09-14-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

neurobo-pharmaceuticals-q2-eps-185-misses-112-estimate
NeuroBo Pharmaceuticals Q2 EPS $(1.85) Mis...
08/14/2024 12:15:51

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimat...

neurobo-pharmaceuticals-completes-enrollment-for-single-ascending-dose-sad-part-1-of-phase-1-trial-for-obesity-treatment-da-1726-no-significant-issues-encountered-enabling-accelerated-start-to-multiple-ascending-dose-mad-part-2-top-line-data-for-sad-expected-in-q3-2024-mad-data-in-q1-2025
NeuroBo Pharmaceuticals Completes Enrollme...
08/13/2024 12:04:02

neurobo-pharmaceuticals-together-with-dong-a-st-and-immunoforge-announces-joint-research-agreement-to-develop-a-long-acting-once-monthly-formulation-of-da-1726-for-the-treatment-of-obesity-financial-terms-of-the-agreement-were-not-disclosed
NeuroBo Pharmaceuticals Together With Dong...
08/06/2024 12:22:54

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Tim...

neurobo-pharmaceuticals-announces-joint-research-agreement-with-dong-a-st-co-ltd-and-immunoforge-to-develop-long-acting-once-monthly-formulation-of-da-1726-for-treatment-of-obesity
NeuroBo Pharmaceuticals Announces Joint Re...
08/06/2024 12:22:51

neurobo-pharmaceuticals-shares-are-trading-higher-after-the-company-signed-an-exclusive-license-agreement-providing--mthera-pharma-co-with-the-rights-to-nb-01
NeuroBo Pharmaceuticals shares are trading...
07/30/2024 12:03:59

neurobo-pharmaceuticals-signs-exclusive-license-agreement-providing-mthera-pharma-co-with-rights-to-nb-01
NeuroBo Pharmaceuticals Signs Exclusive Li...
07/30/2024 12:03:06

watching-neurobo-pharmaceuticals-zacks-small-cap-research-gives-stock-22-price-valuation
Watching NeuroBo Pharmaceuticals; Zacks Sm...
07/01/2024 18:13:35

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07012024_NRBO_Bautz.pdf

neurobo-pharmaceuticals-doses-first-patient-in-mad-part-2-of-phase-1-trial-for-da-1726-in-obesity-treatment-top-line-data-for-part-1-expected-q3-2024-part-2-in-q1-2025-planned-part-3-to-assess-weight-loss-at-24-weeks-70m-financing-to-fund-ongoing-clinical-development
NeuroBo Pharmaceuticals Doses First Patien...
06/26/2024 13:08:02

neurobo-pharmaceuticals-and-2-other-penny-stocks-insiders-are-buying
NeuroBo Pharmaceuticals And 2 Other Penny ...
06/26/2024 12:48:53

dong-a-st-10-buys-254m-shares-of-neurobo-pharmaceuticals-at-avg-price-of-313-total-value-of-79643789
Dong-A ST (10%+) Buys 2.54M Shares of Neur...
06/25/2024 20:24:11

- Form4

neurobo-pharmaceuticals-entered-into-definitive-agreement-for-up-to-70m-concurrent-private-placement-and-registered-direct-offering-of-4325701-shares-at-393share
NeuroBo Pharmaceuticals Entered Into Defin...
06/24/2024 12:03:17

reported-earlier-neurobos-novel-drug-shows-results-for-weight-loss-at-ada-2024
Reported Earlier, NeuroBo's Novel Drug Sho...
06/24/2024 07:05:59

 NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiomet...

neurobo-pharmaceuticals-stock-slides-despite-animal-study-showing-wegvoy-liver-fibrosis-success
NeuroBo Pharmaceuticals Stock Slides Despi...
05/22/2024 14:55:00

NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/22/2024 12:06:41

neurobo-pharmaceuticals-reports-pre-clinical-data-suggesting-da-1241-combined-with-semaglutide-improves-liver-fibrosis-and-demonstrates-additive-hepatoprotective-effects-in-pre-clinical-mash-models-compared-to-either-treatment-alone
NeuroBo Pharmaceuticals Reports Pre-Clinic...
05/22/2024 12:03:41

Data Will be Presented in Two Posters at the EASL Congress 2024

neurobo-pharmaceuticals-q1-2024-gaap-eps-132-misses-110-estimate
NeuroBo Pharmaceuticals Q1 2024 GAAP EPS $...
05/09/2024 12:47:53

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimat...

maxim-group-initiates-coverage-on-neurobo-pharmaceuticals-with-buy-rating-announces-price-target-of-10
Maxim Group Initiates Coverage On NeuroBo ...
05/08/2024 14:08:32

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announc...

neurobo-to-present-latest-pre-clinical-data-on-cardiometabolic-assets-da-1241-and-da-1726-targeting-mash-and-obesity-at-scientific-conferences-in-june
NeuroBo To Present Latest Pre-Clinical Dat...
04/30/2024 12:28:37

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometa...

neurobo-pharmaceuticals-doses-first-patient-in-phase-1-clinical-trial-evaluating-da-1726-for-treatment-of-obesity
NeuroBo Pharmaceuticals Doses First Patien...
04/17/2024 12:06:54

neurobo-pharmaceuticals-files-for-mixed-shelf-offering-of-up-to-150m
NeuroBo Pharmaceuticals Files For Mixed Sh...
04/12/2024 20:13:57

https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm 

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION